Cornish Rosie, Staff Anne Cathrine, Boyd Andy, Lawlor Debbie A, Tretli Steinar, Bradwin Gary, McElrath Thomas F, Hyer Marianne, Hoover Robert N, Troisi Rebecca
Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.
Division of Obstetrics and Gynecology, Oslo University Hospital and University of Oslo, P.O. Box 4956, Nydalen, 0424, Oslo, Norway.
Cancer Causes Control. 2019 Jan;30(1):63-74. doi: 10.1007/s10552-018-1100-6. Epub 2018 Dec 1.
Breast cancer risk associated with pregnancy characteristics may be mediated by maternal hormones or angiogenic factors.
We conducted a prospective breast cancer case-control study among women in the Avon Longitudinal Study of Parents and Children (ALSPAC) and Norwegian Mother and Child Cohort Study (MoBa) related to maternal pregnancy prolactin (n = 254 cases and 374 controls), placental growth factor (PlGF, n = 252 and 371), soluble fms-like tyrosine kinase-1 (sFlt-1, n = 118 and 240) and steroid hormone concentrations (ALSPAC only, n = 173 and 171). Odds ratios (OR) and 95% confidence intervals (CI) for a 1 SD change in analytes were estimated using unconditional logistic regression with matching factors (cohort, mother's birth year, serum/plasma, blood collection timing) and gestational age.
Breast cancer ORs (95% CI) were 0.85 (0.51-1.43) for estradiol, 0.86 (0.67-1.09) for testosterone, 0.89 (0.71-1.13) for androstenedione, 0.97 (0.71-1.34) for hCG, 0.93 (0.75, 1.15) for prolactin, 1.00 (0.78-1.27) for PlGF and 1.91 (1.00-3.65 ALSPAC) and 0.94 (0.73-1.21 MoBa) for sFlt-1, and were similar adjusting for potential confounders. Results were similar by blood collection timing, parity, age at first birth or diagnosis, and time between pregnancy and diagnosis.
These data do not provide strong evidence of associations between maternal hormones or angiogenic factors with subsequent maternal breast cancer risk.
与妊娠特征相关的乳腺癌风险可能由母体激素或血管生成因子介导。
我们在雅芳亲子纵向研究（ALSPAC）和挪威母婴队列研究（MoBa）中对女性进行了一项前瞻性乳腺癌病例对照研究，涉及母体妊娠催乳素（n = 254例病例和374例对照）、胎盘生长因子（PlGF，n = 252和371）、可溶性fms样酪氨酸激酶-1（sFlt-1，n = 118和240）以及类固醇激素浓度（仅ALSPAC，n = 173和171）。使用无条件逻辑回归，并纳入匹配因素（队列、母亲出生年份、血清/血浆、采血时间）和孕周，估计分析物每变化1个标准差时的比值比（OR）和95%置信区间（CI）。
雌二醇的乳腺癌OR（95%CI）为0.85（0.51 - 1.43），睾酮为0.86（0.67 - 1.09），雄烯二酮为0.89（0.71 - 1.13），hCG为0.97（0.71 - 1.34），催乳素为0.93（0.75，1.15），PlGF为1.00（0.78 - 1.27），sFlt-1在ALSPAC中为1.91（1.00 - 3.65），在MoBa中为0.94（0.73 - 1.21），调整潜在混杂因素后结果相似。按采血时间、产次、首次生育或诊断时的年龄以及妊娠与诊断之间的时间划分，结果相似。
这些数据并未提供有力证据表明母体激素或血管生成因子与随后的母体乳腺癌风险之间存在关联。
